Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer

Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news